+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Canada Urothelial Carcinoma Market 2020-2026

  • ID: 5148045
  • Report
  • August 2020
  • Region: Canada
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2021

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • MORE
Canada Urothelial Carcinoma Market Size, Share & Trends Analysis Report by Diagnosis (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (IVP), and Others) and by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other) and Forecast, 2020-2026.

Canada urothelial carcinoma market is estimated to grow modestly at a CAGR of around 8.7% during the forecast period. Canada has a considerable market of urothelial carcinoma treatment due to the increasing healthcare expenditure and significant prevalence of urothelial carcinoma coupled with surging aging population base across the nation. According to Bladder Cancer Canada, bladder cancer is the fifth most common cancer in Canada, being the fourth most common among men and 12th most common among women. Urothelial carcinoma is the most common type of bladder cancer. As per the Canadian Cancer Society, it makes up over 90% of all bladder cancers. It is one of the most expensive cancer treatments in Canada. Therefore, with the growing prevalence of urothelial carcinoma and increasing treatment cost, the urothelial carcinoma market is estimated to foresee significant growth in market value during the forecast period.

Canada urothelial carcinoma market is segmented into diagnosis and treatment. Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. Chemotherapy is the use of a drug, which is used in the treatment of cancer. The chemotherapy is highly adopted as it kills cancer cells that are spread to other parts of the body, far from its primary tumor. The immunotherapy enables the transformation of the patient’s immune system, allow it to attack cancer cells, and either destroy them from growing. Therefore, immunotherapy anticipated exhibiting the fastest growth rate in the urothelial carcinoma market during the forecast period.

The companies which are contributing to the growth of the Canada urothelial carcinoma market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Pfizer, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

Research Methodology:

The market study of the Canada urothelial carcinoma market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation:

1. Canada Urothelial Carcinoma Market Research and Analysis by Diagnosis
2. Canada Urothelial Carcinoma Market Research and Analysis by Treatment

The Report Covers:
  • Comprehensive research methodology of the Canada urothelial carcinoma market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Canada urothelial carcinoma market.
  • Insights about market determinants which are stimulating the Canada urothelial carcinoma market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. Canada Urothelial Carcinoma Market by Diagnosis
5.1.1. Cystoscopy
5.1.2. Biopsy
5.1.3. Urinalysis
5.1.4. Urine Cytology
5.1.5. Intravenous Pyelogram (IVP)
5.1.6. Others (Biomarkers)
5.2. Canada Urothelial Carcinoma Market by Treatment
5.2.1. Surgery
5.2.2. Chemotherapy
5.2.3. Immunotherapy
5.2.4. Radiation Therapy
5.2.5. Others (Targeted Therapy)

6. Company Profiles
6.1. Astellas Pharma Inc.
6.2. AstraZeneca PLC
6.3. Bayer AG
6.4. Bristol-Myers Squibb Co.
6.5. Eli Lilly and Co.
6.6. F. Hoffmann-La Roche Ltd.
6.7. GlaxoSmithKline Plc
6.8. Johnson & Johnson Services, Inc.
6.9. Merck & Co., Inc.
6.10. Pfizer Inc.
6.11. Spectrum Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll